SB 203580，p38 MAPK抑制剂(ab120162)
Key features and details
- p38 MAPK inhibitor
- CAS Number: 152121-47-6
- Purity: > 99%
- Soluble in DMSO to 25 mM
- Form / State: Solid
- Source: Synthetic
概述
-
产品名称
SB 203580，p38 MAPK抑制剂 -
描述
p38 MAPK抑制剂 -
生物学描述
Cell-permeable p38 MAPK inhibitor. Shows selectivity over many other kinases but also shown to have some inhibitory activity against GAK, CK1, RIP2, c-Raf and GSK3.
-
纯度
> 99% -
CAS编号
152121-47-6 -
化学结构
性能
-
化学名称
4-[4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl]pyridine -
分子量
377.43 -
分子式
C21H16FN3OS -
PubChem识别号
176155 -
存放说明
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解度概述
Soluble in DMSO to 25 mM -
处理
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CS(=O)c1ccc(cc1)c2nc(c(n2)c3ccncc3)c4ccc(F)cc4 -
来源
Synthetic
-
研究领域
图片
-
Chemical Structure - SB 203580, p38 MAPK inhibitor (ab120162)2D chemical structure image of ab120162, SB 203580, p38 MAPK inhibitor
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
文献 (30)
ab120162 被引用在 30 文献中.
- Liu X et al. Mitochondria-Targeted Triphenylphosphonium-Hydroxytyrosol Prevents Lipotoxicity-Induced Endothelial Injury by Enhancing Mitochondrial Function and Redox Balance via Promoting FoxO1 and Nrf2 Nuclear Translocation and Suppressing Inflammation via Inhibiting p38/NF-кB Pathway. Antioxidants (Basel) 12:N/A (2023). PubMed: 36671037
- Zhu X et al. PSKH1 affects proliferation and invasion of osteosarcoma cells via the p38/MAPK signaling pathway. Oncol Lett 25:144 (2023). PubMed: 36936027
- Abouleisa RRE et al. A novel small molecule inhibitor of p38⍺ MAP kinase augments cardiomyocyte cell cycle entry in response to direct cell cycle stimulation. Br J Pharmacol 180:3271-3289 (2023). PubMed: 37547998
- Guo P et al. Estrogen Suppresses Cytokines Release in cc4821 Neisseria meningitidis Infection via TLR4 and ERβ-p38-MAPK Pathway. Front Microbiol 13:834091 (2022). PubMed: 35422784
- Alsamri H et al. Carnosol Induces p38-Mediated ER Stress Response and Autophagy in Human Breast Cancer Cells. Front Oncol 12:911615 (2022). PubMed: 35712465